Blood platelets play a central role in haemostasis by leading to plug formation and by increasing the efficiency of blood coagulation. We have previously shown that blood platelets contain a group I1 secretory phospholipase A, (sPLA, grII) which is released into the extracellular medium upon activation but is unable to stimulate blood platelets. We presently reported an investigation of the putative involvement of the human sPLA, grII (hsPLA, grII) in the coagulation process, both in the absence and in the presence of activated platelets. We show that this enzyme prolongs the recalcification time of blood plasma even in the presence of activated platelets.The positive action of blood platelets on coagulation is correlated, at least in part, with the appearence at the cellular surface of procoagulant phospholipids which constitute a potential target for hsPLA, grII. We therefore investigated the involvement of its enzymatic activity in the anticoagulant effect of this enzyme. We observed that the replacement of CaCl, by SrC1, to initiate the coagulation cascade did not suppress, but rather increased, the inhibitory action of hsPLA, grII. Moreover, hsPLA, grII hydrolyzed only a minor proportion of platelet phospholipids, and it did not affect plasma phospholipids. Taken together, these observations strongly suggest that the major action of hsPLA, grII on blood coagulation does not involve the hydrolysis of phospholipids, in contrast with the strong anticoagulant effect of the group I1 venom phospholipase A, from Crotalus durrissus terrificus.We next studied which step of the coagulation cascade was affected by hsPLA, grII. Using purified coagulation factors, we demonstrated that hsPLA, grII strongly inhibited the prothrombinase activity. This inhibitory effect was independent of the presence of phospholipids but required factor Va, leading to the hypothesis that hsPLA, grII inhibited this factor. Further, the anticoagulant effect of hsPLA, grII was observed on normal and factor-X-deficient plasma, but not on factor-V-deficient plasma.In conclusion, the anticoagulant action of hsPLA, grII is based on a nonenzymatic mechanism of action involving the inhibition of factor Va.